Regulus Therapeutics Inc. (RGLS) Financials
RGLS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 37.7 million | 9.5 million |
2023-06-30 | 43.6 million | 9.7 million |
2023-03-31 | 37.0 million | 10.4 million |
2022-12-31 | 46.7 million | 13.4 million |
RGLS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -6.8 million | 973000 |
2023-06-30 | -6.3 million | 382000 |
2023-03-31 | -8.1 million | 410000 |
2022-12-31 | -6.3 million | 397000 |
RGLS Net Income
No data available :(
RGLS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 30.8 million | - | 1.2 million |
2023-06-30 | 37.3 million | - | 1.4 million |
2023-03-31 | 30.3 million | - | 1.6 million |
2022-12-31 | 39.2 million | - | 1.8 million |
RGLS Shares Outstanding
RGLS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 541000 | 5.5 million | 2.6 million | - |
2023-06-30 | - | 5.0 million | 2.3 million | - |
2023-03-31 | 1000 | 4.9 million | 2.4 million | - |
2022-12-31 | 63000 | 4.7 million | 2.2 million | - |
RGLS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | 56000 |
2023-06-30 | - | 47000 |
2023-03-31 | - | 48000 |
2022-12-31 | - | 33000 |
RGLS
Price: $2.43
52 week price:
Earnings Per Share: -1.58 USD
P/E Ratio: -0.89
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 68300
Ebitda: -14.7 millionMarket Capitalization: 169.6 million